{"id":3987,"date":"2026-10-29T09:00:00","date_gmt":"2026-10-29T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3987"},"modified":"2026-10-29T20:08:23","modified_gmt":"2026-10-30T00:08:23","slug":"china-accepts-first-line-her2-adc-filing","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3987","title":{"rendered":"China Accepts First Line HER2 ADC Filing"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Jiangsu Hengrui; Suzhou Shengdiya<\/p>\n

Event Type<\/strong><\/p>\n

Regulatory filing acceptance with priority review (China)<\/p>\n

Modality<\/strong><\/p>\n

HER2-directed antibody-drug conjugate<\/p>\n

Asset<\/strong><\/p>\n

Rezetecan trastuzumab (SHR-A1811)<\/p>\n

Target<\/strong><\/p>\n

HER2<\/p>\n

Disease Area<\/strong><\/p>\n

First-line HER2-positive locally advanced or metastatic breast cancer<\/p>\n

Summary<\/h4>\n

China-originated regulatory signal: Hengrui disclosed on 29 October that NMPA accepted and placed its rezetecan trastuzumab application into priority review for first-line locally advanced or metastatic HER2-positive breast cancer, with or without pertuzumab. This is a review action, not approval or a new data readout.<\/p>\n

The company filing identifies acceptance number CXSS2600174 and subsidiary Suzhou Shengdiya as applicant. It cites randomized open-label Phase III SHR-A1811-307 against docetaxel, trastuzumab and pertuzumab (THP), reporting a significant progression-free-survival advantage for each investigational regimen but no hazard ratio or mature overall-survival figure in this disclosure. The ADC already has three China indications, distinct from this proposed first-line use. Original Chinese publication date is 29 October; no later English syndication is used as the event date.<\/p>\n

Deep Analysis<\/h4>\n

A comparison with active THP is more informative than a single-arm response claim and could support domestic treatment displacement if the benefit, tolerability and survival are persuasive. However, the filing provides no magnitude, toxicity table, discontinuation rate or independent global replication. ADC interstitial lung disease, myelosuppression and payload-related effects require scrutiny. Priority review shortens procedure, not evidentiary requirements. China-only enrollment and local standard-care context may limit regulatory portability abroad; a global bridging or independent trial may be needed.<\/p>\n

Company and Product Background<\/h4>\n

HER2-positive breast cancer is driven by ERBB2 signaling. Rezetecan trastuzumab (SHR-A1811) is a HER2-directed antibody-drug conjugate whose cleavable payload inhibits tumor-cell survival after internalization. Pertuzumab binds a separate HER2 epitope.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> the filing advances a credible first-line ADC challenge, supported by a randomized active-control Phase III and priority review.<\/li>\n
  • Interpretation B:<\/strong> administrative progress says little about net benefit because full efficacy and safety are absent.<\/li>\n
  • Upgrade<\/strong> with a complete Phase III publication, OS and CDE review outcome. Downgrade<\/strong> with substantial toxicity or narrow subgroup benefit. A negative regulatory decision or unfavorable mature survival would falsify<\/strong> broad first-line displacement.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: this is material China regulatory progress; the benefit-risk conclusion remains open.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: neutral pending review. Confidence in Facts: high for issuer filing, moderate without direct regulator docket. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"

    China-originated regulatory signal: Hengrui disclosed on 29 October that NMPA accepted and placed its rezetecan trastuzumab application into priority review for first-line locally advanced or metastatic HER2-positive breast cancer, with or without pertuzumab. This…<\/p>\n","protected":false},"author":1,"featured_media":3991,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1270,1291,498,1292,1293],"class_list":["post-3987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-china-nmpa","tag-hengrui","tag-her2-positive-breast-cancer","tag-rezetecan-trastuzumab","tag-shr-a1811"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3987"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3987\/revisions"}],"predecessor-version":[{"id":3999,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3987\/revisions\/3999"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3991"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}